Clinical Research Directory
Browse clinical research sites, groups, and studies.
2 clinical studies listed.
Filters:
Tundra lists 2 Non-IgM Monoclonal Gammopathy of Undetermined Significance clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.
This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.
NCT07209371
Rifaximin Versus No Intervention for the Treatment of IgG/IgA (Non-IgM) Monoclonal Gammopathy of Undetermined Significance
This phase II trial compares the effect of rifaximin to no intervention for the treatment of IgG/IgA monoclonal gammopathy of undetermined significance (MGUS). Rifaximin is a type of antibiotic that is only used in cancer chemotherapy (antineoplastic antibiotic). It works by damaging the cell's DNA and may kill cancer cells or precancerous cells like those found with MGUS. Giving rifaximin may kill more precancerous cells in patients with IgG/IgA MGUS.
Gender: All
Ages: 18 Years - Any
Updated: 2026-08-17
1 state
NCT07057583
A Study of Carbon 13-based Deep Labelling of Bone Marrow Cells
This study evaluates a novel laboratory method to study how certain bone marrow cells in the body take up nutrients from their environment.
Gender: All
Ages: 18 Years - Any
Updated: 2025-12-19
1 state